As a relatively new means of conducting research in the life sciences, RWE, or real-world evidence, is data that comes from “real world settings” such as a clinical practice. Studies driven by real world evidence, or real-world data (RWD), can utilize data from medical records or claims databases, be conducted prospectively in observational studies or adhere to a mixed, hybrid-design approach.

Two global forces are at odds today – the push for “greener” processes and the demand for lower prices for prescription drugs and materials. Governments and corporations across the globe are adopting policy initiatives and driving scientific innovations to promote sustainable technologies, resulting in an explosion of discoveries based on both chemical- and biocatalytic transformations.

AI’s use in drug discovery is beginning to gain momentum, as seen by the number of large pharmas are already working with smaller AI-based biotechs. Though the term “AI” can carry certain mixed perceptions, scientists within pharma and biotech are starting to realize that AI is poised to make the human element more effective.

Looking to add some scientific content to your day-to-day social media scrolling? We’ve scoured the Internet to bring you Twitter and Instagram accounts that will keep you up to the minute on pharma and biotech events, novel discoveries and new ideas. 

The direct and indirect impact of sourcing human biological samples present serious risks for the scientific research community. Through Compli™ -a governance process that provides standardization, transparency and ensures ethical sourcing through one single service- researchers can now mitigate risk and reduce overhead while implementing a formal compliance process.